A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

AIDS

Volumn 17, Issue 5, 2003, Pages 691-698

  Lalezari, Jacob P ^a   Eron, Joseph J ^b   Carlson, Margrit ^c   Cohen, Calvin ^d   DeJesus, Edwin ^e   Arduino, Roberto C ^f   Gallant, Joel E ^g   Volberding, Paul ^h   Murphy, Robert L ⁱ   Valentine, Fred ^j   Nelson, Emily L ^k   Sista, Prakash R ^k   Dusek, Alex ^k   Kilby, J Michael ^l  

^a Quest Clinical Research   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Comm Res Initiative New England ^*  (United States)

^e IDC Research Initiative   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Trimeris Inc   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

Antiretroviral therapy; Enfuvirtide; Fusion inhibitor; T 20

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; GAMMA GLUTAMYLTRANSFERASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BLEEDING; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; EDEMA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFLAMMATION; INJECTION PAIN; INJECTION SITE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISCOLORATION; VERTIGO; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RNA, VIRAL;

EID: 0037471311     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00007     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999, 179:717-720.
3. Bloor S, Kemp SD, Hertogs K, Alcorn T, Larder BA. Patterns of HIV drug resistance in routine clinical practice: a survey of almost 12000 samples from the USA in 1999 [Abstract]. Antivir Ther 2000, 5 (Suppl. 3):132.
4. Pérez-Alvarez L, Cuevas MT, Villahermosa ML, Pedreira JD, Manjón N, Herrero I, et al. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). J Hum Virol 2001, 4:35-38.
5. Richman DD, Bozzette S, Morton S, Chien S, Wrin T, Dawson K, et al. The prevalence of antiretroviral drug resistance in the US. In: Proceedings and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, USA. 16-19 December 2001 [Abstract LB-17].
6. Blower SM, Aschenbach AN, Gershengom HB, Kahn JO. Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med 2001, 7:1016-1020.
7. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000, 5:41-48.
8. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multi-drug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
9. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990, 249:1533-1544.
10. Montaner JS, Mellors JW. Antiretroviral therapy for previously treated patients. N Engl J Med 2001, 345:452-455.
11. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
12. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
13. Wild C, Greenwell T, Matthews T. A synthetic pepticle from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9:1051-1053.
14. Veronese FD, DeVico AL, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985, 229:1402-1405.
15. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72:986-993.
16. Wei W, Decker J, Liu H, Zhang Z, Arani R, Kilby JM, et al. Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905.
17. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307.
18. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous T-20, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002, 18:685-694.
19. Lalezari J. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:195-197.
20. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
21. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999, 179:808-816.
22. Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional truple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999, 13:F71-F77.
23. Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis 1996, 173:1354-1366.
24. Pilcher CD, Eron JJ, Ngo L, Dusek A, Sista P, Gleavy J, et al. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. AIDS 1999, 13:2171-2173.
25. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med 1995, 122:24-32.
26. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002, 16:327-336.
27. De Clerq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev Med Virol 2000, 10:255-277.
28. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001, 183:1121-1125.
29. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquired Immune Defic Syndr 2000, 25:99-102.